Skip to content

Tolbutamide

DRUG13 trials

Sponsors

AstraZeneca, Eli Lilly and Company, National Cancer Institute (NCI), Boehringer Ingelheim, Janssen Research & Development, LLC

Conditions

Adult Solid NeoplasmAdvanced CancerChronic PainDrug Drug InteractionDrug Interaction PotentialDrug-drug InteractionHealthyHealthy Volunteers

Phase 1

AZD2066 Cocktail Study
CompletedNCT00930306
AstraZenecaChronic Pain
Start: 2009-06-30End: 2009-09-30Updated: 2009-10-27
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
TerminatedNCT01185548
Eli Lilly and CompanyAdvanced Cancer, Lymphoma
Start: 2010-07-31End: 2010-12-31Updated: 2018-10-19
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
CompletedNCT01218620
National Cancer Institute (NCI)Adult Solid Neoplasm
Start: 2010-09-30End: 2014-12-31Updated: 2014-12-23
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
CompletedNCT01525628
Boehringer IngelheimHepatitis C, Chronic
Start: 2012-04-30End: 2014-10-31Updated: 2016-06-10
Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers
TerminatedNCT02182401
Boehringer IngelheimHealthy
Start: 2009-07-31Updated: 2014-07-18
A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
CompletedNCT02211079
Janssen Research & Development, LLCHealthy
Start: 2014-09-30End: 2014-11-30Updated: 2015-11-24
A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS
CompletedNCT02473627
Daiichi SankyoHealthy
Start: 2015-05-31End: 2015-07-31Updated: 2015-11-05
A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers
CompletedNCT03103568
Swedish Orphan BiovitrumDrug Drug Interaction
Start: 2017-03-28End: 2017-07-24Updated: 2017-08-10
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
CompletedNCT03291288
Daiichi SankyoDrug Interaction Potential
Start: 2018-02-26End: 2021-04-16Updated: 2021-05-14
Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
CompletedNCT03457597
Corcept TherapeuticsHealthy
Start: 2018-03-06End: 2018-04-28Updated: 2018-05-17
Drug Interaction Study of CT1812 in Healthy Volunteers
CompletedNCT03716427
Cognition TherapeuticsHealthy Volunteers
Start: 2016-11-10End: 2017-02-15Updated: 2018-10-23
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
CompletedNCT03723395
Seagen Inc.Drug-drug Interaction
Start: 2018-09-17End: 2018-12-28Updated: 2019-12-18
Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide
CompletedNCT05097716
PfizerHealthy Volunteers
Start: 2021-11-02End: 2022-01-10Updated: 2023-10-06

Related Papers